SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): March
19,
2007
Arrhythmia
Research Technology, Inc.
(Exact
name of issuer as specified in its charter)
|
Delaware
(State
or other jurisdiction of Incorporation or
organization)
|
1-9731
(Commission
File Number)
|
72-0925679
(I.R.S.
Employer Identification
Number)
|
25
Sawyer
Passway
Fitchburg,
MA 01420
(Address
of principal executive offices and zip code)
(978)
345-5000
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
2.02. Results of Operations and Financial
Condition
On
March
19, 2007, the Company issued a press release announcing its financial results
for the fourth quarter and year ended December 31, 2006. The press release
is
attached as Exhibit 99.1 to this report.
The
information set forth in the above Item 2.02 and the attached Exhibit 99.1
is
furnished to, but shall not be deemed “filed” with the Commission for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the
Exchange Act), or otherwise incorporated by reference into any filing pursuant
to the Securities Act of 1933, as amended, or the Exchange Act, except as
otherwise expressly stated in such a filing.
Item
9.01. Financial Statements and
Exhibits
(d).
Exhibits
|
Exhibit
Number
|
Description
|
|
|
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Fitchburg, Commonwealth of Massachusetts,
on the
22nd day of March 2007.
| |
|
|
| |
ARRHYTHMIA
RESEARCH TECHNOLOGY, INC. |
|
|
|
| |
By: |
/s/ David
A. Garrison |
| |
David A. Garrison
|
| |
Executive Vice President and
Chief Financial Officer
|
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
|